GlassScriptPhysician profile
Miguel Chuquilin
NPI 1982633251
$30,446.00
in general payments reported to CMS, 2019-2025
21 companies · $3,884 in 2025
The $3,884 reported for 2025 was more than what 86% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.00 · 2021: $1,148 · 2022: $2,138 · 2023: $172 · 2024: $23K · 2025: $3,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $3,456 · Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,201.25 |
| Travel and Lodging | $3,456.11 |
| Food and Beverage | $2,425.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $10,948.23 | 2019-2025 | Ultomiris |
| Sarepta Therapeutics, INC. | $10,232.38 | 2024 | |
| Amgen INC. | $2,609.18 | 2025 | Uplizna |
| Argenx US, INC. | $2,301.29 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Biotech, INC. | $1,797.65 | 2024-2025 | |
| Ucb, INC. | $1,434.86 | 2024-2025 | Zilbrysq, Nayzilam |
| Tg Therapeutics, INC. | $310.16 | 2025 | |
| Medtronic, INC. | $165.76 | 2025 | Inceptiv |
| Janssen Scientific Affairs, LLC | $125.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.05 | 2025 | Hyqvia |
| Sk Life Science, INC. | $70.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $52.44 | 2025 | Rexulti |
| Neurelis, INC. | $47.49 | 2024-2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $42.98 | 2025 | Wainua |
| Pfizer INC. | $42.78 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $42.25 | 2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $34.41 | 2025 | |
| Neurocrine Biosciences, INC. | $28.99 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $24.46 | 2025 | Austedo Xr |
| Horizon Therapeutics Plc | $23.73 | 2023 | Uplizna |
| Genentech USA, INC. | $21.91 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Chuquilin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.